94 results
Page 4 of 5
424B5
u7mlkokyzqp
2 Aug 19
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
pguyr
1 Aug 19
Viking Therapeutics Reports Second Quarter 2019 Financial Results and Provides Corporate Update
4:24pm
8-K
EX-99.1
yil56kk949bik5m5 ytf
2 Jul 19
Viking Therapeutics Appoints Kathy Rouan, Ph.D., to Board of Directors
4:15pm
8-K
EX-99.1
qe4c3yml gs
2 May 19
Viking Therapeutics Reports First Quarter 2019 Financial Results and Provides Corporate Update
4:05pm
8-K
EX-99.1
5tpnzqiv2
13 Mar 19
Viking Therapeutics Reports Fourth Quarter and Year-End 2018 Financial Results and Provides Corporate Update
4:12pm
8-K
EX-99.1
a355cxdyeyx
7 Nov 18
Viking Therapeutics Reports Third Quarter 2018 Financial Results and Provides Corporate Update
12:00am
424B5
6yvvqg774251dw iu
21 Sep 18
Prospectus supplement for primary offering
4:16pm
8-K
EX-99.1
4rqkjs
21 Sep 18
Viking Therapeutics Announces Pricing of $175.8 Million Public Offering of Common Stock
6:05am
424B5
gnpnohjm 1pkd
19 Sep 18
Prospectus supplement for primary offering
4:27pm
8-K
EX-99.1
3pxet88fsy fjz2uvl
9 Aug 18
Viking Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update
12:00am
8-K
EX-99.1
6ol659h
12 Jun 18
Viking Therapeutics Announces Closing of Public Offering of Common Stock
7:10am
424B5
pcbmikcs84odlx108wl
7 Jun 18
Prospectus supplement for primary offering
5:13pm
8-K
EX-99.1
e7z0vmego4nc
7 Jun 18
Viking Therapeutics Announces Pricing of $67.5 Million Public Offering of Common Stock
1:41pm